dc.contributor.author |
Kovács, Gábor |
|
dc.contributor.author |
Wachtel A |
|
dc.contributor.author |
Basharova E |
|
dc.contributor.author |
Spinelli T |
|
dc.contributor.author |
Nicolas P |
|
dc.contributor.author |
Kabickova E |
|
dc.date.accessioned |
2018-06-20T12:41:52Z |
|
dc.date.available |
2018-06-20T12:41:52Z |
|
dc.date.issued |
2017 |
|
dc.identifier |
85028573236 |
|
dc.identifier.citation |
pagination=1685-1698;
journalVolume=13;
journalIssueNumber=19;
journalTitle=FUTURE ONCOLOGY; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/5437 |
|
dc.identifier.uri |
doi:10.2217/fon-2017-0189 |
|
dc.description.abstract |
Aim: To investigate across multiple cycles the efficacy and safety of palonosetron in the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients receiving highly or moderately emetogenic chemotherapy (HEC/MEC). Patients & methods: Patients were randomly assigned to 10, 20 mu g/kg palonosetron or 3 x 150 mu g/kg ondansetron for up to four cycles of HEC/MEC. Results: In all on-study chemotherapy cycles, complete response rates were higher in patients in the 20 mu g/kg palonosetron group than the ondansetron group. Treatment-emergent adverse events were comparable between the palonosetron 20 mu g/kg and ondansetron groups. Conclusion: Over four cycles of HEC/MEC, 20 mu g/kg palonosetron was an efficacious and safe treatment for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients. |
|
dc.relation.ispartof |
urn:issn:1479-6694 |
|
dc.title |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study |
|
dc.type |
Journal Article |
|
dc.date.updated |
2018-05-14T13:33:46Z |
|
dc.language.rfc3066 |
en |
|
dc.identifier.mtmt |
3341373 |
|
dc.identifier.wos |
000409493600005 |
|
dc.identifier.pubmed |
28569078 |
|
dc.contributor.department |
SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika |
|
dc.contributor.institution |
Semmelweis Egyetem |
|